McCabe 1988.

Study characteristics
Methods	Randomised, 2‐period cross‐over trial
Participants	36 (9 men/27 women) aged 18‐69 years (median = 48 years) Tumour types: breast cancer (11 people), haematological malignancies (9 people), sarcomas (6 people), gastrointestinal malignancies (5 people), melanoma (2 people), ovarian cancer (2 people), testicular cancer (1 person) Chemotherapy regimens: doxorubicin (13 people), cyclophosphamide, methotrexate and 5‐fluorouracil (7 people), nitrogen mustard, vincristine, procarbazine and prednisone (7 people), platinum combinations (4 people), DTIC (2 people), 5‐fluorouracil combinations (2 people), 5‐azacytadine (1 person). No information on doses reported Chemotherapy emetogenicity: moderate to high
Interventions	Dronabinol 15 mg/m2 1 hour prior to chemotherapy, then every 4 hours for 24 hours after chemotherapy orally, n = 36 Prochlorperazine 10 mg 1 hour prior to chemotherapy, then every 4 hours for 24 hours after chemotherapy orally, n = 36
Outcomes	Episodes of nausea and vomiting during 24 hours, feeling high, dizziness, dysphoria, hallucination, paranoia
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	All people were analysed
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	High risk	"Blinding not achieved"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Study not blinded